Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "compliance"

544 News Found

Brenntag to showcase latest pharma innovation at CPHI India 2025
News | November 25, 2025

Brenntag to showcase latest pharma innovation at CPHI India 2025

A key highlight will be Brenntag’s qualified amino acids portfolio


Ind-Swift Laboratories receives certifications from Bureau Veritas
Sustainability | November 24, 2025

Ind-Swift Laboratories receives certifications from Bureau Veritas

These certifications reflect the company's continuous commitment to maintaining international standards of environmental sustainability as well as occupational health and safety


Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification
News | November 21, 2025

Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification

Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub


Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market
News | November 18, 2025

Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market

Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers


Indian pharma sector poised for a global leap beyond generics: K. Raja Bhanu, DG, PHARMEXCIL
News | November 17, 2025

Indian pharma sector poised for a global leap beyond generics: K. Raja Bhanu, DG, PHARMEXCIL

With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards


Lupin receives EIR from FDA for its Aurangabad facility
News | November 13, 2025

Lupin receives EIR from FDA for its Aurangabad facility

The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.


Shilpa Medicare announces positive Phase 3 results for Oeris
Clinical Trials | November 12, 2025

Shilpa Medicare announces positive Phase 3 results for Oeris

OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days